Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Get Free Report) released its quarterly earnings results on Friday. The company reported ($1.23) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.78, Zacks reports.
Neuphoria Therapeutics Inc. – Common Stock Stock Up 7.4 %
Shares of NASDAQ NEUP opened at $4.94 on Friday. Neuphoria Therapeutics Inc. – Common Stock has a 1 year low of $2.12 and a 1 year high of $15.96.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright increased their price objective on shares of Neuphoria Therapeutics Inc. – Common Stock from $8.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, February 4th.
About Neuphoria Therapeutics Inc. – Common Stock
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Read More
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- What is the Euro STOXX 50 Index?
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- 3 Small Caps With Big Return Potential
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
- P/E Ratio Calculation: How to Assess Stocks
- MarketBeat Week in Review – 02/10 – 02/14
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
